REPLIMUNE GROUP INC
REPLNASDAQTrading Snapshot
- Day Range
- $18.70 β $19.50
- 52-Week Range
- $1.50 β $23.54
- Volume (shares)
- 1,964,451
- Avg Volume (shares)
- β
- Shares Outstanding
- 94.8M
- Next Earnings
- 2027-02-01
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -6.8
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.58
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +14.1%
REPLIMUNE GROUP INC
REPLAbout REPLIMUNE GROUP INC
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

Wall Street Analysts Think Replimune Group (REPL) Could Surge 29.51%: Read This Before Placing a Bet
The consensus price target hints at a 29.5% upside potential for Replimune Group (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions co

REPL Stock Up 80% in a Month on Tudriqev Launch & Pipeline Progress
Replimune shares surge 80% as Tudriqev's commercial launch gains traction, earnings beat expectations and pipeline progress strengthens growth prospects.

Short Interest Powder Kegs: 10 Stocks Bears Cannot Quit Buying
Bears are crowding into a small group of stocks, and one name has nearly its entire float sold short.

Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade
The mean of analysts' price targets for Replimune Group (REPL) points to a 26.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising

Replimune: 3 Key Takeaways for Long-Term Investors
Replimune ended the second quarter with $307.8 million in cash. Over 15 institutions wrote prescriptions within 20 business days.

Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript
Replimune Group, Inc. ( REPL ) Q2 2027 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Arleen Goldenberg Sushil Patel - CEO & Director Michelle DiNapoli - Chief Commercial Officer Emily Hill - Chief Finan